Due Diligence and Art

Due Diligence and Art

Share this post

Due Diligence and Art
Due Diligence and Art
Arcturus self-amplifying RNA: US approval expected this year.
mRNA, Gene Therapies and Biomanufacturing Fraud

Arcturus self-amplifying RNA: US approval expected this year.

saRNA platform Kostaive is already approved in Europe and Japan and is being tested in the US now.

Sasha Latypova's avatar
Sasha Latypova
Jun 11, 2025
∙ Paid
222

Share this post

Due Diligence and Art
Due Diligence and Art
Arcturus self-amplifying RNA: US approval expected this year.
227
38
Share

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies:

  • LUNAR® lipid-mediated delivery;

  • STARR® mRNA technology (sa-mRNA);

  • mRNA drug substance and drug product manufacturing.

Arcturus KOSTAIVE, a self-amplifying messenger RNA (sa-…

Keep reading with a 7-day free trial

Subscribe to Due Diligence and Art to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Sasha Latypova
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share